These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26674744)

  • 1. Regulatory exclusivities for medicinal products for human use in the EU.
    Schoonderbeek C; Jong B
    Pharm Pat Anal; 2016; 5(1):5-8. PubMed ID: 26674744
    [No Abstract]   [Full Text] [Related]  

  • 2. Legal instruments supporting the development of orphan medicinal products in the European Union.
    Miaskowska-Daszkiewicz K
    Acta Pol Pharm; 2014; 71(1):181-7. PubMed ID: 24779206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishing rarity in the context of orphan medicinal product designation in the European Union.
    Tsigkos S; Hofer MP; Sheean ME; Mariz S; Larsson K; Naumann-Winter F; Fregonese L; Sepodes B
    Drug Discov Today; 2018 Mar; 23(3):681-686. PubMed ID: 28647377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European regulation on orphan medicinal products: 10 years of experience and future perspectives.
    ; Westermark K; Holm BB; Söderholm M; Llinares-Garcia J; Rivière F; Aarum S; Butlen-Ducuing F; Tsigkos S; Wilk-Kachlicka A; N'Diamoi C; Borvendég J; Lyons D; Sepodes B; Bloechl-Daum B; Lhoir A; Todorova M; Kkolos I; Kubáčková K; Bosch-Traberg H; Tillmann V; Saano V; Héron E; Elbers R; Siouti M; Eggenhofer J; Salmon P; Clementi M; Krieviņš D; Matulevičiene A; Metz H; Vincenti AC; Voordouw A; Dembowska-Bagińska B; Nunes AC; Saleh FM; Foltánová T; Možina M; Torrent i Farnell J; Beerman B; Mariz S; Evers MP; Greene L; Thorsteinsson S; Gramstad L; Mavris M; Bignami F; Lorence A; Belorgey C
    Nat Rev Drug Discov; 2011 May; 10(5):341-9. PubMed ID: 21532564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The legal regulation of life cycle of orphan pharmaceuticals].
    Gildeyeva GN; Kartavtsova TV
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2014; (3):37-42. PubMed ID: 25219041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EU orphan regulation--ten years of application.
    Michaux G
    Food Drug Law J; 2010; 65(4):639-69, i-ii. PubMed ID: 24479246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.
    Joppi R; Bertele' V; Garattini S
    Eur J Clin Pharmacol; 2013 Apr; 69(4):1009-24. PubMed ID: 23090701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Navigating through orphan medicinal product regulations in EU and US--similarities and differences.
    Tiwari J
    Regul Toxicol Pharmacol; 2015 Feb; 71(1):63-7. PubMed ID: 25497996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hope for patients with rare diseases--"orphan" drugs].
    Kuzelová M; Kubácková K; Palágyi M; Smíd M
    Cas Lek Cesk; 2006; 145(4):296-300. PubMed ID: 16639930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [European ordinance on orphan drugs: changes and threats].
    Linthorst GE; Hollak CE
    Ned Tijdschr Geneeskd; 2003 Jan; 147(4):143-5. PubMed ID: 12635543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orphan Drug Regulation: A missed opportunity for children and adolescents with cancer.
    Vassal G; Kearns P; Blanc P; Scobie N; Heenen D; Pearson A
    Eur J Cancer; 2017 Oct; 84():149-158. PubMed ID: 28818704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The problem of orphan drugs.
    Ferner RE; Hughes DA
    BMJ; 2010 Nov; 341():c6456. PubMed ID: 21081597
    [No Abstract]   [Full Text] [Related]  

  • 14. Regulatory Considerations Toward Orphan Drug Designation and Orphan Drug Exclusivity in the United States and European Union: Structural Similarity, Clinical Superiority/Significant Benefit, and Case Studies.
    Roberts SW; Elvang TLB; Syed L; Samuelsen MB; Arp-Hansen EL; Nielsen HK; Lund IK; Dünweber DL; Listov-Saabye N; Bjørn-Larsen D; Hjelmsmark A; Mikkelsen TA
    Ther Innov Regul Sci; 2023 Mar; 57(2):386-395. PubMed ID: 36401076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory and Evidence Requirements and the Changing Landscape in Regulation for Marketing Authorisation.
    Pignatti F; Péan E
    Recent Results Cancer Res; 2019; 213():169-187. PubMed ID: 30543013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The new European regulation on pediatric medicines: regulatory perspective.
    Hawcutt DB; Smyth RL
    Paediatr Drugs; 2008; 10(3):143-6. PubMed ID: 18454566
    [No Abstract]   [Full Text] [Related]  

  • 17. [Orphan drugs: availability, reliability and reimbursement].
    Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
    Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EU marketing authorization review of orphan and non-orphan drugs does not differ.
    Putzeist M; Mantel-Teeuwisse AK; Llinares J; Gispen-De Wied CC; Hoes AW; Leufkens HG
    Drug Discov Today; 2013 Oct; 18(19-20):1001-6. PubMed ID: 23835230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matched analysis on orphan drug designations and approvals: cross regional analysis in the United States, the European Union, and Japan.
    Murakami M; Narukawa M
    Drug Discov Today; 2016 Apr; 21(4):544-9. PubMed ID: 26945941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orphan drugs. EU regulations.
    Mariz S; Llinares J; Westermark K
    BMJ; 2011 Jan; 342():d136. PubMed ID: 21224321
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.